In Puerto Rico, costs send pharma packing

Poor Puerto Rico. Pharmaceuticals firms are shutting down plants in the U.S. territory, eliminating some 3,000 jobs. Reasons for the closures include Big Pharma's worldwide restructuring, Puerto Rico's expiring tax breaks and high utility bills. Already, Teva Pharmaceuticals, GlaxoSmithKline, Schering-Plough, Watson Pharmaceuticals and Bristol-Myers Squibb have either shuttered facilities or announced plans to do so.

Local lawmakers could remedy the situation by offering new industrial tax breaks to replace an IRS provision that expired last year, but they've been unable to agree on a new approach.

- read this report for more

Related Article:
GSK plant closure begins 5,000 job cuts. Report

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.